Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML

Trial Profile

Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Cytarabine (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Idarubicin (Primary) ; Plerixafor (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms PLERIFLAG
  • Most Recent Events

    • 23 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 May 2016 This trial is Completed in Spain, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top